Madeleine Hordinski for Business Insider
Kristi Turner had lost 108 pounds on Zepbound when her insurer cut her off.
Getty Images; Alyssa Powell/BI
The copycat weight-loss drugs party was supposed to be over, but it's still raging on.
Octavio Jones for BI
Tassii/Getty Images
Sandy Huffaker for The Washington Post via Getty Images

As Novo Nordisk and Eli Lilly struggle to keep up with soaring demand for their popular diabetes and weight loss drugs, healthcare companies are introducing supply trackers to help patients navigate ongoing shortages.

The millennial-skewed telehealth platform Hims & Hers announced Monday that is now offering customers a compounded version of semaglutide, the active ingredient in popular weight loss drugs like Ozempic and Wegovy.